Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
338 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
22 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
23 Temporarily not available An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Condition: HIV
Intervention: Drug: PRO 140
24 No longer available Expanded Access to ANG1005 for Individual Patients
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Breast Cancer With Recurrent Brain Metastases;   Leptomeningeal Carcinomatosis
Intervention: Drug: ANG1005
25 Available Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Condition: Fecal Incontinence
Intervention: Device: magnetic anal sphincter augmentation for fecal incontinence
26 Available Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Condition: Non-Hodgkin's B-cell Lymphoma
Intervention: Drug: MT-3724
27 No longer available SARC021C: A Continuation Study of TH-CR-406/SARC021
Condition: Soft Tissue Sarcoma
Intervention: Drug: Th-302
28 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
29 Available Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma
Condition: Urothelial Carcinoma Ureteral Location
Intervention: Drug: MitoGel
30 Available Low-profile Visualized Intraluminal Support -HUD
Condition: Giant Wide Necked Aneurysms
Intervention: Device: Low Profile Visualized Intraluminal Support Device
31 Approved for marketing Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries
Condition: Peripheral Arterial Disease
Intervention: Device: Atherectomy followed by Drug Eluting Balloon (DEB)
32 Available Expanded Access Protocol Using HBOC-201
Condition: Anemia
Intervention: Biological: HBOC-201
33 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
34 Available Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
Condition: Epilepsy
Intervention: Drug: Cannabidiol
35 Available Compassionate Use of Deferiprone in Patients With PKAN
Condition: Pantothenate Kinase-Associated Neurodegeneration
Intervention: Drug: Deferiprone
36 Available Protocol for Continued Patient Access to Study Drug
Condition: Cancer
Intervention: Drug: LY2503029
37 Available Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
Conditions: Acute Myeloid Leukemia (AML) With;   FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Intervention: Drug: Midostaurin
38 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
39 Available Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition: Adenovirus
Intervention: Drug: Brincidofovir
40 No longer available A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)
Condition: Non-small-cell Lung Cancer With Somatic EGFR Mutations
Intervention: Other: Collection of tumor and blood specimen

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years